[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"open-angle-glaucoma-oag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:open-angle-glaucoma-oag":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,77,105,129,157,184,217,240,264,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100625147","comparison-of-goniotomy-device-outcomes-in-combined-phacoemulsification-goniotomy-surgeries-100625147",false,"NCT07418853","Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries","Inclusion Criteria: Adults ≥ 18 years old\n\n* Diagnosed with primary or secondary open-angle glaucoma (e.g., POAG, pigmentary, pseudoexfoliative)\n* Scheduled for phacoemulsification with planned goniotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Angle-closure glaucoma\n\n  * Prior glaucoma surgery in the study eye\n  * Planned stand-alone goniotomy\n  * Inability to comply with follow-up schedule","ALL","18 Years",{"count":18,"type":19},132,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this study is to determine of one of three different devices to perform goniotomy to treat glaucoma at the time of cataract surgery is more or less effective than the others. The primary outcomes are to compare intraocular pressure control and glaucoma medication use up to 6 months after surgery. Participants will under combined cataract surgery and goniotomy. They will have post-operative follow up visits at 1 day, 1 week, 1 month, 3 months, and 6 month",[25,26,27],"Open Angle Glaucoma (OAG)","Primary Open Angle Glaucoma (POAG)","Secondary Open Angle Glaucoma","NOT_YET_RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":19},"2026-07-01",{"date":36,"type":19},"2028-03-01",{"name":38,"class":39},"Henry Ford Health System","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100615256","phase-1-evaluating-er-100-for-safety-in-people-with-glaucoma-or-non-arteritic-anterior-ischemic-optic-neuropathy-optic-nerve-conditions-100615256","NCT07290244","Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)","A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]","Inclusion Criteria:\n\n* Have clear eye structures and be able to have your pupils safely dilated so the doctor can examine the back of your eye.\n* Able to understand the study and sign a consent form.\n* Be between 40 and 85 years old.\n* Willing and able to follow the study schedule, including all visits and tests, and speak a language for which the study materials are available.\n* If a participant can become pregnant, must agree to use a condom and one highly effective form of birth control during sex for at least 4 months after receiving the study drug (ER-100).\n\nFor participants with open-angle glaucoma (OAG):\n\n* Diagnosis of open-angle glaucoma in the study eye.\n* Eye pressure must be less than 30 mmHg, measured with a standard test.\n* Visual field test must show moderate to advanced vision loss (MD score between -6 and -20 dB).\n* Not expected to need glaucoma surgery in the study eye within 2 months after receiving ER-100.\n* Have reasonably good vision in the study eye (at least 20\u002F80 on a standard eye chart).\n\nFor participants with NAION (non-arteritic anterior ischemic optic neuropathy):\n\n* Had a sudden, painless loss of vision in one eye within 14 days before receiving ER-100, confirmed by a specialist. Having had NAION in the other eye is okay.\n* The affected eye must show swelling of the optic nerve.\n* Visual field test must show vision loss consistent with optic nerve damage (MD worse than -3.0 dB).\n* If only one eye is affected, there must be a difference in pupil response between the two eyes.\n* Have vision in the affected eye between 20\u002F40 and 2\u002F500 on a standard eye chart.\n\nExclusion Criteria:\n\n* History of optic neuritis (inflammation of the optic nerve) or repeated episodes of eye inflammation (uveitis) not caused by injury or surgery.\n* Allergic reactions to tetracycline antibiotics or steroid medications.\n* Moderate to severe cataracts, macular problems, or corneal issues that could interfere with eye testing.\n* Unable to keep your eyes focused on a target during testing.\n* Had cataract surgery or other eye surgery (including laser procedures) within 3 months before receiving the study drug.\n* Had cancer (except for basal cell skin cancer) within the past 5 years.\n* Have Type 1 diabetes, or poorly controlled Type 2 diabetes (A1c greater than 7 despite treatment).\n* Have memory or thinking problems that prevent you from understanding the study or completing the required tests.\n* Pregnant or breastfeeding.\n* Have a weakened immune system, including a history of organ transplant, or test positive for HIV, hepatitis B or C, or tuberculosis.\n* Have any other condition that, in the opinion of the study doctor, could increase your risk from the study drug or procedures, affect the study results, or make it hard for you to complete the study.\n* Have macular disease, advanced diabetic eye disease, or other eye conditions that limit vision in the study eye.\n* Eye pressure at screening is 30 mmHg or higher.\n* Taking certain medications (warfarin, dilantin, carbamazepine, or barbiturates) within 14 days before starting the study or during the first 8 weeks.\n* Have any other eye or vision problem that, in the opinion of the study doctor, could affect safety or interfere with vision testing.\n* Have previously received any gene therapy using adeno-associated virus (AAV).\n\nAdditional Exclusion Criteria for Participants with Open-Angle Glaucoma (OAG):\n\n\\- Diagnosed with glaucoma before age 40.\n\nAdditional Exclusion Criteria for Participants with NAION:\n\n* Show signs of giant cell arteritis (a type of blood vessel inflammation), based on abnormal blood tests.\n* Had NAION start in both eyes at the same time.","40 Years","85 Years",{"count":51,"type":19},18,[53],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are:\n\n* Is ER-100 safe when given as a single dose to people with OAG or NAION\n* What side effects may occur, if any, after taking ER-100?\n\nParticipants will:\n\n* Receive a single dose of ER-100\n* Undergo safety assessments including detailed eye examination and laboratory tests\n* Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body\n* Complete questionnaires about their quality of life\n* Be followed for up to 5 years to monitor long-term health and vision outcomes",[25,56],"NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)",[58,59,60,61,62,63,64],"Optic Neuropathy","Retinal Diseases","Aging\u002FCellular Aging","Open-Angle Glaucoma","Non-Arteritic Anterior Ischemic Optic Neuropathy","Partial Epigenetic Reprogramming","Epigenetic Therapy","RECRUITING","2026-05-15",{"date":68,"type":32},"2026-05-19",{"date":70,"type":32},"2026-03-02",{"date":72,"type":19},"2032-03",{"name":74,"class":75},"Life Biosciences Inc.","INDUSTRY",4,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100624324","direct-vs-standard-slt-for-glaucoma-a-noninferiority-trial-100624324","NCT07408154","Direct vs Standard SLT for Glaucoma: A Noninferiority Trial","A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of OAG (including exfoliative or pigmentary) or OHT\n* Gonioscopically open angle (visible scleral spur 360°)\n* Ability to consent and comply with follow-up\n\nExclusion Criteria:\n\n* Angle-closure or secondary glaucomas\n* IOP \\>35 mmHg despite therapy\n* Corneal pathology interfering with laser or IOP measurement\n* Recent ocular surgery (\\\u003C6 months)\n* Contraindications to study medications or procedures\n* Cognitive impairment preventing consent",{"count":85,"type":19},172,[22],"This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.",[89,90],"Open-angle Glaucoma (OAG)","Ocular Hypertension (OHT)",[92,61,93,94,95],"Glaucoma","Ocular Hypertension","Laser Trabeculoplasty","Intraocular Pressure","2026-05-04",{"date":98,"type":32},"2026-05-06",{"date":100,"type":32},"2026-04-27",{"date":102,"type":19},"2027-10",{"name":104,"class":39},"Medical University of South Carolina",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100623768","observational-trial-of-the-updated-inserter-for-the-travoprost-intracameral-implant-75mcg-100623768","NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg","TRIO","Inclusion Criteria:\n\n* Diagnosis of Open-angle glaucoma\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Subject who is breast-feeding or pregnant",{"count":114,"type":19},30,"OBSERVATIONAL","Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)",[25,118],"Ocular Hypertension (OH)",[92,93],"2026-02-24",{"date":122,"type":32},"2026-02-27",{"date":124,"type":32},"2025-12-17",{"date":126,"type":19},"2026-07",{"name":128,"class":75},"Glaukos Corporation",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":20,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":40},"100620196","phase-2-single-site-pilot-study-evaluating-the-effect-of-qls-111-ophthalmic-solution-on-posterior-perfusion-and-vessel-dilation-100620196","NCT07354477","Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","(PENGUIN)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.\n* Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20\u002F200).\n* Able and willing to give signed informed consent and follow study instructions.\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG, mild to moderate NTG, or stable NPDR.\n* Patient is using more than 1 ocular hypotensive topical medication for intraocular pressure (IOP) control (prior MIGS and\u002For laser trabeculoplasty to control IOP is allowed if done at least 3 months from Screening (Visit 1).\n* Use of TO β-blockers (i.e. timolol) within 3 months prior to Screening.\n* Is noncompliant with current ocular anti-hypotensive medications and\u002For unwilling to be compliant throughout the study.\n* Clinically significant severe retinal disease in either eye that will require treatment during the study (e.g., proliferative diabetic retinopathy, exudative, or severe non-exudative macular degeneration). NOTE: background diabetic retinopathy (BDR) as required for the NPDR subjects is allowed if in the Investigator's opinion the BDR is stable and is expected to remain stable during the duration of the study.\n* Anti-VEGF or TO steroid treatment within 3 months prior to Screening or expected treatment while participating in this study. Prior diabetic macular edema (DME) history is allowed if adequately controlled with treatment (anti-VEGFs and steroids not within last 3 months prior to Screening), regimen is stable, and not expected to change during the study. - Corneal pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, and bullae) in either eye that would inhibit accurate IOP measurements.\n* Previously diagnosed, clinically significant systemic or psychiatric disease (e.g., myasthenia gravis, hepatic, renal, endocrine, pulmonary, or cardiovascular disorders) which might compromise the study results or subject safety. For the purpose of this study previously diagnosed, clinically significant renal disease that should be excluded from enrollment will be defined as Stages 3-5 kidney disease and\u002For an estimated glomerular filtration rate (eGFR) of ≤59.\n* Use of calcium channel blockers.\n* Labile hypertension and\u002For hypotension that is inadequately controlled,",{"count":138,"type":19},14,[140],"PHASE2","Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG",[143,89,144],"Non-proliferative Diabetic Retinopathy (NPDR)","Normal Tension Glaucoma (NTG)",[146,147,148],"glaucoma","diabetic retinopathy","vessel dilation","2026-02-21",{"date":120,"type":32},{"date":152,"type":32},"2026-02-20",{"date":154,"type":19},"2026-06",{"name":156,"class":75},"Qlaris Bio, Inc.",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":15,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":20,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100617971","istent-inject-versus-goniotomy-with-kahook-dual-blade-in-glauocma-treatment-100617971","NCT07325552","iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment","iStent Inject Versus Goniotomy With Kahook Dual Blade in Patients With Ocular Hypertension and Glaucoma","iSKDB","Inclusion Criteria:\n\n* Only one eye per participant\n* Clinically significant cataract\n* Glaucoma or intraocular hypertension treated with one to four medications and no need for filtering glaucoma surgery at the time of study enrollment.\n* Open chamber angle with Schaffer grading three to four in at least two quadrants\n\nExclusion Criteria:\n\n* Previous glaucoma surgery, including cyclodestructive procedures.\n* Selective Laser Trabeculoplasty (SLT) within 90 days prior to planned surgery.\n* Exudative age-related macular degeneration, proliferative diabetic retinopathy, clinically significant corneal dystrophy, other eye disease that affect intraocular eye pressure or visual field.\n* Unable to participate and make written consent due to another medical condition.","18 Weeks",{"count":167,"type":19},100,[22],"The purpose of the study is to investigate the efficacy of cataract surgery in combination with Kahook Dual Blade Glide goniotomy (KDB) or iStent Inject W Trabecular Microbypass Stent (Istent) in eyes with Open-angle glaucoma.",[25],[146,172,173],"iStent inject","Kahook Dual Blade goniotomy","2026-01-07",{"date":176,"type":32},"2026-01-08",{"date":178,"type":32},"2026-01-01",{"date":180,"type":19},"2028-01-01",{"name":182,"class":39},"Medical University of Bialystok",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":15,"minAge":191,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":20,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":40},"100616072","dslt-in-normal-tension-glaucoma-ntg-asian-eyes-100616072","NCT07300852","DSLT in Normal Tension Glaucoma (NTG) Asian Eyes","The Effectiveness of DSLT in Asian Normal Tension Glaucoma Patients","Inclusion Criteria:\n\n* Asian descent\n* NTG diagnosis: glaucomatous optic neuropathy in patients with IOP measurements consistently lower than 21 mmHg\n* Mean deviation (MD) of the visual field between 0 to -12dB\n* No significant central vision loss within 5 degrees within 5th percentile\n* Age ≥20 years\n* NTG patients who are medically controlled on 1-3 medications and safe to wash out or IOP is still insufficient from medications and safe to washout\n* Shaffer grade II or more on 3 of the 4 quadrants\n* Central corneal thickness (CCT) 450-600µm\n* All participants are able to provide written informed consent before participation\n\nExclusion Criteria:\n\n* Angle closure glaucoma or narrow angle status post laser peripheral iridotomy (LPI), or any other open angle glaucoma excluding NTG\n* History of SLT within last 2 years\n* History intraocular surgery including refractive surgery, except for history of cataract surgery that has been greater than 1 year\n* Patients anticipating cataract surgery during the study follow-up period\n* Unable to have DSLT procedure due to pre-limbal findings\n* Any presence of relevant ocular diseases including retinal disease with no confirmed cure","20 Years",{"count":193,"type":19},40,[22],"The goal of this clinical trial is to evaluate the efficacy of direct selective laser trabeculoplasty (DSLT) or laser treatment in Asian patients with normal tension glaucoma. The main question it aims to answer is:\n\nDoes the DSLT reduce intraocular pressure (IOP) and medication use in Asian NTG subjects? Participants will attend routine follow-up visits with their eye surgeon and glaucoma testing such as optical coherence tomography (OCT) imaging and visual field test(s) after the laser study treatment.",[144,92,25,197],"Glaucoma, Open Angle",[199,200,201,92,202,203,204,205,206,207,208],"DSLT","Direct Selective Laser Trabeculoplasty","NTG","Normal Tension Glaucoma","BELKIN Vision Eagle","Glaucoma laser treatment","Asian glaucoma","Intraocular pressure","SLT alternative","Glaucoma medications reduction","2025-12-20",{"date":211,"type":32},"2025-12-24",{"date":178,"type":19},{"date":214,"type":19},"2028-03-31",{"name":216,"class":39},"Ngoc Nguyen Inc.",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":15,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":20,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":237,"locationsCount":239},"100609922","safety-and-effectiveness-of-the-visiplate-aqueous-shunt-in-patients-with-refractory-open-angle-glaucoma-100609922","NCT07220876","Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma","A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial of the Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma","Inclusion Criteria:\n\n* Open angle, pseudoexfoliative or pigmentary glaucoma\n* IOP at preoperative visit of ≥ 20mmHg and ≤ 40mmHg\n* Visual field mean deviation score of -3dB or worse\n* Area of healthy, free and mobile conjunctiva in the target quadrant\n* Shaffer angle grade ≥ 2 in the target quadrant\n\nExclusion Criteria:\n\n* Angle closure glaucoma\n* Congenital, neovascular or other secondary glaucomas\n* Previous intraocular surgery, with the exception of uncomplicated cataract surgery\n* Previous glaucoma shunt\u002Fvalve in the target quadrant\n* Clinically significant inflammation or infection in the study eye within 30 days prior to the operative visit\n* History of corneal surgery, corneal opacities or corneal disease\n* Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition","45 Years",{"count":226,"type":19},165,[22],"A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial",[25],[92],"2025-12-08",{"date":233,"type":32},"2025-12-15",{"date":235,"type":32},"2025-11-07",{"date":102,"type":19},{"name":238,"class":75},"Avisi Technologies Inc.",12,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":15,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":40},"100587857","dslt-performance-in-treatment-nave-patients-with-newly-diagnosed-open-angle-glaucoma-100587857","NCT06933836","DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma","How Does First Line Treatment With DSLT Perform in Treatment-naïve Patients With Newly Diagnosed Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Primary open angle glaucoma\n* Patients age 30 or greater with an IOP of 18-26 mmHg\n* Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)\n* DSLT procedure\n\nExclusion Criteria:\n\n* History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery\n* Angle closure patients\n* Ocular Hypertension\n* Baseline VF MD of worse than -12dB\n* Uncontrolled systemic microvascular disease (eg. HTN, DM)\n* Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)","30 Years",{"count":249,"type":19},55,"DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.",[25],[92,199,253],"Interocular Pressure","2025-04-16",{"date":256,"type":32},"2025-04-18",{"date":258,"type":32},"2025-03-31",{"date":260,"type":19},"2027-12-31",{"name":262,"class":263},"Barnet Dulaney Perkins Eye Centers","NETWORK",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":20,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":40},"100582586","efficacy-and-safety-of-gonioscopy-assisted-transluminal-trabeculotomy-in-patients-with-primary-open-angle-glaucoma-and-cataract-100582586","NCT06865235","Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract.","Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract - a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients aged 40 years or older,\n* Previously included in the glaucoma departments of the participating institutions,\n* Indication for cataract surgery, diagnosed by clinical examination with visual acuity (VA) equal to or worse than 20\u002F40,\n* Primary Open Angle Glaucoma (POAG), determined by the presence of typical visual field (VF) defects and\u002For by the aspect of the optic nerve observed at fundoscopy or retinography (increased vertical optical excavation with thinning of the neural rhyme, asymmetry of the cup\u002Fdisc ratio greater than 0.2, localized loss (\"notch\") or defect in the retinal nerve fiber layer (\"Hoyt\")).\n* APIC classification with amplitude greater\u002Fequal to 2 and pigmentation less than 4 on gonioscopy.\n* Intraocular pressure (IOP) less than or equal to 25 mmHg before washout of hypotensive eye drops.\n* IOP between 22 and 30 mmHg after washout of hypotensive eye drops or with a history of IOP greater than or equal to 21 mmHg in more than one previous care described in the medical record.\n\nExclusion Criteria:\n\nPatients who have any of the following situations:\n\n* Severe glaucoma, determined according to the Hoddap-Parrish-Anderson criteria;\n* Axial diameter greater than 26 mm or less than 21.00 mm;\n* Endothelial count less than 1500 cc;\n* Pachymetry less than 480 or greater than 600 microns;\n* Patients undergoing some type of intraocular surgery or laser procedure in the preoperative period and\u002For after these procedures in the postoperative period;\n* Those who present some important per-operative complication during the study.\n* With high risk of progression, the so-called rapid progressors, who are patients with high IOPs even with the use of many medications, regardless of the severity of the nerve injury.",{"count":272,"type":19},90,[22],"Prospective, randomized, , double-blind, clinical trial, comparing the variation of intraocular pressure (IOP) of patients with mild or moderate primary open-angle glaucoma (OAG) and cataract divided into three groups. All study participants should be treated for the pathology with one or more hypotensive medications or, regardless of the number of drugs, when IOP is greater than 20 mmHg and less than 26 mmHg. The two-year follow-up should also compare the reduction in the number of medications used, reoperation rate, adverse effects, visual acuity, endothelial loss, induction of astigmatism, variation in IOP according to axial diameter of the eye, anterior chamber and age, in addition to the existence of change in the quality of life of patients in the postoperative period",[25],[277,278,279,280,281,282,283,284],"Open angle glaucoma","Cataract","OAG","Goniotomy assisted transluminal trabeculotomy","GATT","trabeculotomy","Goniotomy","hemi-gatt","2025-03-05",{"date":287,"type":32},"2025-03-07",{"date":289,"type":32},"2024-05-07",{"date":291,"type":19},"2028-02",{"name":293,"class":39},"Faculdade de Ciências Médicas de Minas Gerais",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":40},"100569231","long-term-safety-and-efficacy-of-a-modified-suprachoroidal-silicone-tube-sst-shunt-100569231","NCT06691555","Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt","The Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt in Patients with Primary Open-angle Glaucoma (POAG) and Pseudo-exfoliative Glaucoma (PXG) Over an Extended Follow-up Period","Inclusion Criteria:\n\n* Previously were treated with Suprachoroidal silicone tube shunt\n* Willing and able to participate in this cross sectional observational follow up\n* Participant capable of giving informed consent\n\nExclusion Criteria:\n\n* Condition that could impact the ability of the participant to attend a follow-up visit as per the discretion of the investigator","90 Years",{"count":303,"type":19},66,"The goal of this observational study is to evaluate the long-term safety and efficacy of a modified suprachoroidal silicone tube (SST) shunt in treating patients with primary open-angle glaucoma (POAG) and pseudo-exfoliative glaucoma (PXG).\n\nThe main questions it aims to answer are:\n\nDoes the SST shunt maintain intraocular pressure (IOP) reduction over an extended follow-up period? What is the effect of the SST shunt on endothelial cell count (ECC) and overall corneal health?\n\nParticipants will:\n\nUndergo intraocular pressure (IOP) measurements Have their endothelial cell count (ECC) evaluated Complete assessments of best corrected visual acuity (BCVA) Be assessed for C\u002FD ratio Be monitored for adverse events or shunt-related complications over time",[92,25,306,93,307,308],"POAG","Exfoliation Syndrome","Choroidal Effusions",[310,311,92,61,312,313,314],"MIGS","Suprachoroidal Space","Suprachoroidal Silicone Tube","Suprachoroidal Shunt","Glaucoma Shunt","2024-11-14",{"date":317,"type":32},"2024-11-15",{"date":319,"type":32},"2024-11-08",{"date":321,"type":19},"2024-11-30",{"name":323,"class":39},"Davinci LTD"]